Prashasti Agrawal

Prashasti Agrawal serves as a Clinical Assistant Professor and Assistant Attending in the Department of Medicine at Memorial Sloan Kettering Cancer Center, with specialized affiliations in the Solid Tumor Oncology Division, Thoracic Oncology group, and Hematology-Oncology Fellows program. Her clinical and research work centers on complex malignancies including mesothelioma and thoracic cancers.

Dr. Agrawal's research spans hematologic and solid tumor oncology with deep expertise in mesothelioma subtypes, immunotherapy mechanisms, and targeted therapeutic approaches. She actively investigates rare presentations like testicular mesothelioma while developing novel vaccine-based interventions such as WT1-targeted therapies combined with checkpoint inhibitors. Her work bridges clinical practice and translational research through MSK's integrated oncology divisions.

Analysis of her 2025 publications reveals a concentrated focus on therapeutic innovation for difficult-to-treat cancers, particularly through radiation combination strategies for oligometastatic disease and first-in-human vaccine trials. These studies consistently emphasize biomarker-driven patient selection and outcomes measurement in mesothelioma and lung cancer contexts.

Dr. Agrawal maintains extensive collaborations within MSK's oncology ecosystem, particularly with Michael Offin (4 co-authored works) and Jessica Sauter (3 co-authored works), as evidenced by her participation in multidisciplinary thoracic oncology research teams focused on pleural malignancies and immunotherapeutic approaches.